SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

UroGen Pharma Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.01 per share

(Title of Class of Securities)

M96088105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

M96088105

Names of Reporting Persons

The Toronto-Dominion Bank

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,616,714.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,616,714.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

2,616,714.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.4 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP Number(s):

M96088105

Names of Reporting Persons

TD SECURITIES INC.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,306.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,306.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,306.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

0 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

UroGen Pharma Ltd.

(b)

Address of issuer's principal executive offices:

9 HA'TA'ASIYA ST, RA'ANANA, ISRAEL 4365007

Item 2.

(a)

Name of person filing:

The Toronto-Dominion Bank TD SECURITIES INC.

(b)

Address or principal business office or, if none, residence:

The principal office address of The Toronto-Dominion Bank ("TD Bank"): 66 Wellington Street West 12th Floor TD Tower Toronto, Ontario, Canada M5K 1A2 The principal office address of TD Securities Inc. ("TDSI"): 55 King Street West TD Tower 12th Floor Toronto, Ontario, Canada M5K 1A2

(c)

Citizenship:

The Toronto-Dominion Bank - CANADA (FEDERAL LEVEL) TD SECURITIES INC. - ONTARIO, CANADA

(d)

Title of class of securities:

Ordinary Shares, par value NIS 0.01 per share

(e)

CUSIP Number(s):

M96088105

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

TD Bank - Bank TDSI - Broker Dealer

Item 4.

Ownership

(a)

Amount beneficially owned:

2,618,020 TD Bank has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of 2,616,714 of these shares and TDSI has the sole power to vote or direct the vote and the sole power to dispose or direct the disposition of 1,306 of these shares. This schedule is jointly filed by TD Bank and TDSI. TD Bank is the sole owner of TDSI. TD Bank may be deemed to hold an indirect interest in the shares reported herein by TDSI by virtue of its ownership of TDSI. TD Bank disclaims ownership of the shares reported herein by TDSI except to the extent of its pecuniary interest therein. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

(b)

Percent of class:

5.4 %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The Toronto-Dominion Bank - 2,616,714 TD SECURITIES INC. - 1,306

(ii) Shared power to vote or to direct the vote:

The Toronto-Dominion Bank - 0 TD SECURITIES INC. - 0

(iii) Sole power to dispose or to direct the disposition of:

The Toronto-Dominion Bank - 2,616,714 TD SECURITIES INC. - 1,306

(iv) Shared power to dispose or to direct the disposition of:

The Toronto-Dominion Bank - 0 TD SECURITIES INC. - 0

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Toronto-Dominion Bank

Signature:	Christina Petrou
Name/Title:	Christina Petrou / Executive Vice President & Chief Operating Officer
Date:	05/15/2026

TD SECURITIES INC.

Signature:	Greg Nowakowski
Name/Title:	Greg Nowakowski / Chief Compliance Officer
Date:	05/15/2026

Exhibit Information

Exhibit I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares of UroGen Pharma Ltd. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Dated: May 15, 2026 THE TORONTO-DOMINION BANK By: /s/ Christina Petrou Title: Executive Vice President & Chief Operating Officer TD SECURITIES INC. By: /s/ Greg Nowakowski Title: Chief Compliance Officer

SEC Form SCHEDULE 13G filed by UroGen Pharma Ltd.